We have always provided precision treatment for every man with prostate cancer who comes through our doors. Now, surgical innovation, dramatic improvements in imaging, better understanding of molecular biomarkers, more accurate biopsy techniques and more precise diagnosis have come together to allow us to provide truly individualized treatment. This means that we can tell a man with confidence that he can safely enter active surveillance; it also makes us far less likely to miss significant cancer that needs to be treated, and for men at higher risk, it gives us the opportunity to offer additional treatments aimed at curing their disease and maximizing their quality of life.
Milestones: I am proud to report that H. Ballentine Carter and Trinity Bivalacqua have received two of the highest awards in our field. Bal Carter has retired after a remarkable 32 years at the Brady, but his legacy will continue for many more years, thanks to a research fund established in his name. We continue to lead the field in treatment and research in bladder, kidney, and testicular cancer, and to treat an ever-broader range of patients who, not so many years ago, would have had incurable disease.
Alan W. Partin, M.D., Ph.D.
The Jakurski Family Director and Professor
The James Buchanan Brady Urological Institute
Urologist-in-Chief, Johns Hopkins Medicine